Insider Purchases: Inside the Buy
Tag: Speculative Stocks
Tilray of Sunshine: CEO Bought Shares Weeks Ago — and Now Earnings Are Finally Rolling In
Tilray finally posted profits and a healthy cash flow — and insiders bought in early. Could this be the long-awaited turnaround, or just another puff of smoke?
Absci: When AI Meets Antibodies — and Insiders Can’t Resist Buying More!
AI is designing drugs, and Absci is leading the charge — with insider confidence, top-tier partners, and a cash runway through 2028. Still pre-revenue but packed with promise, this biotech might just be the next NVIDIA of antibodies.
Eastman Kodak (KODK): Insider Buys, Debt Drama & a Pivot to Pills?!
Eastman Kodak insiders are snapping up shares, with CEO Jim Continenza leading the charge. But Kodak’s finances are shaky, its debt heavy, and its pivot to pharmaceuticals uncertain. High risk, high reward — or just a faded picture?
CEO Bought Shares: Is Full House Worth Betting the House?
Full House Resorts is growing fast—but still bleeding cash. The CEO’s massive insider buy may hint at a turnaround, but with debt looming and expansion plans on the table, is FLL worth a gamble? We break it down—odds, icons, and all.